Alpha 1-Antitrypsin Deficiency, AATD, (NCT06677307)

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

Tags

Lipid-based nanoparticleAlpha-1 Antitrypsin Deficiency, AATDOther rare inherited disordersRNA editingADAR (adenosine deaminase acting on RNA)Korro BioTrialsClinical